JP2022535429A5 - - Google Patents

Info

Publication number
JP2022535429A5
JP2022535429A5 JP2021571993A JP2021571993A JP2022535429A5 JP 2022535429 A5 JP2022535429 A5 JP 2022535429A5 JP 2021571993 A JP2021571993 A JP 2021571993A JP 2021571993 A JP2021571993 A JP 2021571993A JP 2022535429 A5 JP2022535429 A5 JP 2022535429A5
Authority
JP
Japan
Prior art keywords
cells
cell population
genetically modified
genetically
population according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571993A
Other languages
English (en)
Japanese (ja)
Other versions
JP7629414B2 (ja
JP2022535429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035752 external-priority patent/WO2020247392A1/en
Publication of JP2022535429A publication Critical patent/JP2022535429A/ja
Publication of JP2022535429A5 publication Critical patent/JP2022535429A5/ja
Priority to JP2025015446A priority Critical patent/JP2025081360A/ja
Application granted granted Critical
Publication of JP7629414B2 publication Critical patent/JP7629414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571993A 2019-06-04 2020-06-02 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ Active JP7629414B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015446A JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962857167P 2019-06-04 2019-06-04
US62/857,167 2019-06-04
US201962943697P 2019-12-04 2019-12-04
US62/943,697 2019-12-04
PCT/US2020/035752 WO2020247392A1 (en) 2019-06-04 2020-06-02 Combinations of engineered natural killer cells and engineered t cells for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015446A Division JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Publications (3)

Publication Number Publication Date
JP2022535429A JP2022535429A (ja) 2022-08-08
JP2022535429A5 true JP2022535429A5 (enExample) 2023-06-09
JP7629414B2 JP7629414B2 (ja) 2025-02-13

Family

ID=73652681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571993A Active JP7629414B2 (ja) 2019-06-04 2020-06-02 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
JP2025015446A Pending JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015446A Pending JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Country Status (7)

Country Link
US (1) US20220233593A1 (enExample)
EP (1) EP3980450A4 (enExample)
JP (2) JP7629414B2 (enExample)
CN (1) CN114174325A (enExample)
AU (1) AU2020288829A1 (enExample)
CA (1) CA3140393A1 (enExample)
WO (1) WO2020247392A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2021146147A1 (en) * 2020-01-13 2021-07-22 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
MX2022015586A (es) * 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
WO2022040577A1 (en) * 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
US20240299542A1 (en) * 2021-01-05 2024-09-12 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
JP2024513313A (ja) * 2021-03-08 2024-03-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ＣＤ６６ｅポリペプチドに結合する分子
JP2024517641A (ja) * 2021-04-20 2024-04-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 免疫細胞の遺伝子改変および治療的使用のための方法および組成物
WO2022242701A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified gamma-delta t cells and uses thereof
WO2022242700A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified nk cells and uses thereof
KR20240051112A (ko) * 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CN117730094A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
US20260152721A1 (en) * 2021-11-04 2026-06-04 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
TW202405165A (zh) * 2022-04-14 2024-02-01 日商第一三共股份有限公司 編碼膜型細胞激素及tnf受體超家族分子之細胞內域的多核苷酸
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115948341B (zh) * 2022-11-28 2025-05-16 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2012136231A1 (en) 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
EP3805371A1 (en) * 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
WO2016094679A1 (en) * 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3256494A4 (en) * 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
AU2016374497B2 (en) * 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
MX2018010484A (es) * 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
SG10201912519VA (en) * 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
CN107602703B (zh) * 2016-08-12 2021-03-23 四川大学 靶向人EpCAM的基因工程化淋巴细胞及其制备方法和用途
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3532075A4 (en) * 2016-10-27 2020-07-08 Intima Bioscience, Inc. VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
CN106755107B (zh) * 2016-11-22 2019-10-01 上海健信生物医药科技有限公司 一种car新分子及其在肿瘤治疗中的应用
WO2018118494A2 (en) * 2016-12-22 2018-06-28 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
CN117363636A (zh) * 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN108728459B (zh) * 2017-04-24 2023-08-04 上海恒润达生生物科技股份有限公司 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
CA3081456A1 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CN109608547B (zh) * 2017-12-29 2022-03-15 郑州大学第一附属医院 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用
CN109608548A (zh) * 2017-12-29 2019-04-12 郑州大学第附属医院 基于人源cd20抗体的嵌合抗原受体、慢病毒表达载体及其应用
ES3052818T3 (en) * 2018-02-09 2026-01-14 Us Health Tethered interleukin-15 and interleukin-21
SG11202010763VA (en) * 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
CN110724199B (zh) * 2018-07-17 2023-12-05 成都盛世君联生物技术有限公司 Nkg2d car-t细胞及其制备和应用
AU2019386140B2 (en) * 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
BR112021016046A2 (pt) * 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP4778585A2 (en) * 2019-05-07 2026-07-22 Gracell Bioscience (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
AU2020321354A1 (en) * 2019-07-31 2022-03-03 Nkarta, Inc. Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
CA3163258A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells

Similar Documents

Publication Publication Date Title
Kloess et al. CAR-expressing natural killer cells for cancer retargeting
Kim et al. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells
JP2022548943A5 (enExample)
JP2022550899A5 (enExample)
JP2023552998A5 (enExample)
Morgan et al. Adoptive cell therapy: genetic modification to redirect effector cell specificity
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
TWI905347B (zh) 用於調變ｃａｒ－ｔ活性之方法與組成物
CN115058395B (zh) 嵌合抗原受体(car)、组合物及其使用方法
Birkholz et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer
JP2023505206A5 (enExample)
JP2021513347A5 (enExample)
JP2021505131A5 (enExample)
JP2021519061A5 (enExample)
IL270415B2 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2022510207A5 (enExample)
JP2022184852A5 (enExample)
Quandt et al. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
JP2023516300A5 (enExample)
IL300729B1 (en) An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
JP2023548467A5 (enExample)
JP2020511529A5 (enExample)
JP2017535284A5 (enExample)
JP2023549098A5 (enExample)
JP2020507349A5 (enExample)